BR112018072389A2 - anticorpos que reconhecem tau - Google Patents

anticorpos que reconhecem tau

Info

Publication number
BR112018072389A2
BR112018072389A2 BR112018072389-4A BR112018072389A BR112018072389A2 BR 112018072389 A2 BR112018072389 A2 BR 112018072389A2 BR 112018072389 A BR112018072389 A BR 112018072389A BR 112018072389 A2 BR112018072389 A2 BR 112018072389A2
Authority
BR
Brazil
Prior art keywords
antibodies
tau
recognize tau
recognize
retard
Prior art date
Application number
BR112018072389-4A
Other languages
English (en)
Inventor
Barbour Robin
James Dolan Philip
Liu Yue
ALEXANDER Svetlana
Renz Mark
Original Assignee
Prothena Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Limited filed Critical Prothena Biosciences Limited
Publication of BR112018072389A2 publication Critical patent/BR112018072389A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

a invenção provê anticorpos que se ligam especificamente à tau. os anticorpos inibem ou retardam as patologias associadas à tau e à deterioração sintomática associada.
BR112018072389-4A 2016-05-02 2017-05-02 anticorpos que reconhecem tau BR112018072389A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330789P 2016-05-02 2016-05-02
US62/330,789 2016-05-02
PCT/IB2017/052544 WO2017191560A1 (en) 2016-05-02 2017-05-02 Antibodies recognizing tau

Publications (1)

Publication Number Publication Date
BR112018072389A2 true BR112018072389A2 (pt) 2019-02-19

Family

ID=58709515

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072389-4A BR112018072389A2 (pt) 2016-05-02 2017-05-02 anticorpos que reconhecem tau

Country Status (20)

Country Link
US (3) US10889638B2 (pt)
EP (1) EP3452508A1 (pt)
JP (2) JP2019525724A (pt)
KR (1) KR102471787B1 (pt)
CN (1) CN109219615B (pt)
AU (1) AU2017259038A1 (pt)
BR (1) BR112018072389A2 (pt)
CA (1) CA3022515A1 (pt)
CL (1) CL2018003112A1 (pt)
CO (1) CO2018012986A2 (pt)
CU (1) CU24537B1 (pt)
EA (1) EA201892417A1 (pt)
IL (1) IL262726B1 (pt)
MX (1) MX2018013384A (pt)
PE (1) PE20190261A1 (pt)
PH (1) PH12018502054A1 (pt)
SG (1) SG11201808434WA (pt)
UA (1) UA124148C2 (pt)
WO (1) WO2017191560A1 (pt)
ZA (1) ZA201808044B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
CN107849124B (zh) 2015-06-05 2021-09-24 基因泰克公司 抗tau抗体及使用方法
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
EA201892417A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
KR20230070336A (ko) 2016-05-02 2023-05-22 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
CA3044679A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
AU2018263935A1 (en) 2017-05-02 2019-12-19 Prothena Biosciences Limited Antibodies recognizing tau
KR20200058480A (ko) 2017-10-16 2020-05-27 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 및 그의 용도
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
EP3877410A4 (en) * 2018-11-08 2022-08-10 Prothena Biosciences Limited ANTIBODIES FOR DETECTING TAU
AU2018448903A1 (en) * 2018-11-08 2021-05-20 Prothena Biosciences Limited Antibodies recognizing tau
JP2022524588A (ja) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
JP2023526500A (ja) 2020-05-19 2023-06-21 オター プロシーナ リミテッド アルツハイマー病の処置のためのマルチエピトープワクチン
EP4291234A1 (en) * 2021-02-14 2023-12-20 Prothena Biosciences Limited Methods of using antibodies recognizing tau
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AU690092B2 (en) 1992-12-14 1998-04-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
FR2755144B1 (fr) * 1996-10-29 1998-11-27 Rhone Poulenc Rorer Sa Fragments d'anticorps a chaine unique anti-p53 et utilisation
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
ES2333069T3 (es) 1997-03-10 2010-02-16 Ottawa Hospital Research Institute Uso de acidos nucleicos que contienen dinucleotido cpg no metilado en combinacion con alumbre como adyuvante.
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE60036082T2 (de) 1999-02-05 2008-06-12 Samsung Electronics Co., Ltd., Suwon Verfahren und vorrichtung zur wiederauffindung von texturbildern
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
WO2004016655A1 (ja) 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation 中枢性タウ蛋白質特異的抗体
WO2004050884A2 (de) 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
US7847146B2 (en) 2003-03-28 2010-12-07 Baylor College Of Medicine Model for neurodegenerative disorders
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US20050132424A1 (en) 2003-10-21 2005-06-16 Envivo Pharmaceuticals, Inc. Transgenic flies expressing Abeta42-Dutch
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
PT1820022E (pt) 2004-11-10 2009-08-05 Boehringer Ingelheim Pharma Utilização de análise por citometria de fluxo para optimizar estratégias de conservação de bancos de células cho
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
ATE500276T1 (de) 2004-12-30 2011-03-15 Us Gov Health & Human Serv Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
JP2009539406A (ja) 2006-06-16 2009-11-19 エンビボ ファーマシューティカルズ インコーポレイテッド タウおよびアミロイド前駆体断片を発現する遺伝子組換えハエ
WO2007147213A1 (en) 2006-06-22 2007-12-27 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
WO2008022153A2 (en) 2006-08-14 2008-02-21 The Regents Of The University Of California Inhibitors of pde4 and methods of use
KR20150067395A (ko) 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
SI2436696T1 (sl) 2007-01-05 2017-10-30 University Of Zurich Anti-beta-amiloidno protitelo in načini njegove uporabe
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
MY148472A (en) 2007-03-02 2013-04-30 Boehringer Ingelheim Pharma Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP2009056790A (ja) 2007-09-03 2009-03-19 Takao Otogawa ファイル用ポケット
RU2504551C2 (ru) 2007-09-26 2014-01-20 УЗ ФАРМА ГмбХ Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
US9272030B2 (en) * 2007-10-17 2016-03-01 Janssen Sciences Ireland Uc Use of tau to monitor immunotherapy
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
JP2010014691A (ja) 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
SG193216A1 (en) 2008-08-18 2013-09-30 Amgen Fremont Inc Antibodies to ccr2
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
TWI614267B (zh) 2009-05-13 2018-02-11 建新公司 抗人類ｃｄ５２免疫球蛋白
CN102596221B (zh) 2009-06-10 2019-06-04 纽约大学 病理tau蛋白的免疫靶向
US20110045534A1 (en) 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
JP6124591B2 (ja) 2009-08-28 2017-05-10 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
EP2512600A2 (en) 2009-12-18 2012-10-24 Amgen Inc. Wise binding agents and epitopes
US8945576B2 (en) * 2010-01-08 2015-02-03 Kyoto University Vaccine for treatment of tautopathy
AR080243A1 (es) 2010-02-23 2012-03-21 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
ITRM20100320A1 (it) 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
US20120023911A1 (en) 2010-07-28 2012-02-02 Gm Global Technology Operations, Inc. Detection of exhaust particulate filter substrate failure
EA031698B1 (ru) 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
EP2673635A4 (en) 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
EP2701743A4 (en) 2011-04-27 2015-08-19 Univ Northwestern SELECTIVE ANTIBODIES FOR TAU PATHOLOGICAL DIMERS AND PRE-FIBRILLARY TAU PATHOLOGICAL OLIGOMERS AND THEIR USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
ES2656442T3 (es) 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
TWI573590B (zh) 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
KR101981351B1 (ko) * 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
TWI605060B (zh) 2012-03-28 2017-11-11 賽諾菲公司 抗緩激肽ｂ１受體配位體之抗體
AU2013243861A1 (en) 2012-04-05 2014-10-23 Ac Immune S.A. Humanized Tau antibody
US9428864B2 (en) 2012-04-18 2016-08-30 E I Du Pont De Nemours And Company Multilayered sheet
EP2870176A4 (en) 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
US9567395B2 (en) 2012-08-16 2017-02-14 Ipierian, Inc. Methods of treating a tauopathy
US20140056901A1 (en) * 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP4356927A2 (en) * 2012-10-12 2024-04-24 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US9364191B2 (en) 2013-02-11 2016-06-14 University Of Rochester Method and apparatus of spectral differential phase-contrast cone-beam CT and hybrid cone-beam CT
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
US11761959B2 (en) * 2013-03-15 2023-09-19 The Trustees Of The University Of Pennsylvania Blood biomarker that predicts persistent cognitive dysfunction after concussion
CA2903091C (en) 2013-03-15 2022-09-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2015027082A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
CN111569063A (zh) 2013-11-27 2020-08-25 伊皮埃里安股份有限公司 治疗tau病变的方法
EP3080611B1 (en) 2013-12-13 2018-11-14 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
RS60443B1 (sr) 2013-12-17 2020-07-31 Genentech Inc Anti-cd3 antitela i postupci upotrebe
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US20150253341A1 (en) 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
EA036307B1 (ru) 2014-06-26 2020-10-23 Янссен Вэксинс Энд Превеншн Б.В. Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3221349B1 (en) * 2014-11-19 2020-11-04 Axon Neuroscience SE Humanized tau antibodies in alzheimer's disease
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US10202444B2 (en) 2015-02-24 2019-02-12 Rpeptide, Llc Anti-tau antibodies
CN107849124B (zh) 2015-06-05 2021-09-24 基因泰克公司 抗tau抗体及使用方法
US20200030445A1 (en) 2015-06-12 2020-01-30 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US11327080B2 (en) 2015-07-21 2022-05-10 BioArctic Neruoscience AB Method for treatment of traumatic brain injury targeting aggregated peptides
AU2016334051B2 (en) 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
KR20230070336A (ko) 2016-05-02 2023-05-22 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
EA201892417A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
WO2018085653A1 (en) 2016-11-04 2018-05-11 The Regents Of The University Of California Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
CA3044679A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
US11319372B2 (en) 2017-02-21 2022-05-03 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
JP7109467B2 (ja) 2017-03-28 2022-07-29 ヤンセン ファッシンズ アンド プリベンション ベーフェー タウに特異的に結合する結合分子
CN117205311A (zh) 2017-03-28 2023-12-12 基因泰克公司 治疗神经退行性疾病的方法
AU2018263935A1 (en) 2017-05-02 2019-12-19 Prothena Biosciences Limited Antibodies recognizing tau
AU2017418317A1 (en) 2017-06-16 2019-12-05 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
KR20200058480A (ko) 2017-10-16 2020-05-27 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 및 그의 용도
AU2018364630A1 (en) 2017-11-09 2020-05-21 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
EP3720490A1 (en) 2017-12-04 2020-10-14 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
AU2019237252A1 (en) 2018-03-23 2020-10-22 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
CA3095443A1 (en) 2018-03-28 2019-10-03 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
EP3784274A1 (en) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
EP3877410A4 (en) 2018-11-08 2022-08-10 Prothena Biosciences Limited ANTIBODIES FOR DETECTING TAU
AU2018448903A1 (en) 2018-11-08 2021-05-20 Prothena Biosciences Limited Antibodies recognizing tau
WO2020106598A1 (en) 2018-11-19 2020-05-28 The Board Of Regents Of The University Of Texas System Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies
SG11202106717PA (en) 2019-02-08 2021-07-29 Prothena Biosciences Ltd Antibodies recognizing tau
JP2022524588A (ja) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
WO2021010712A1 (ko) 2019-07-15 2021-01-21 주식회사 아델 항-타우 항체 및 이의 용도

Also Published As

Publication number Publication date
UA124148C2 (uk) 2021-07-28
AU2017259038A1 (en) 2018-10-11
EP3452508A1 (en) 2019-03-13
CO2018012986A2 (es) 2018-12-14
CN109219615A (zh) 2019-01-15
JP2022169598A (ja) 2022-11-09
US20190330314A1 (en) 2019-10-31
CU24537B1 (es) 2021-07-02
US11584791B2 (en) 2023-02-21
MX2018013384A (es) 2019-02-28
KR20190003647A (ko) 2019-01-09
KR102471787B1 (ko) 2022-11-29
CU20180136A7 (es) 2019-06-04
US20210130449A1 (en) 2021-05-06
US10889638B2 (en) 2021-01-12
PH12018502054A1 (en) 2019-06-24
SG11201808434WA (en) 2018-10-30
EA201892417A1 (ru) 2019-05-31
ZA201808044B (en) 2020-02-26
CN109219615B (zh) 2022-12-09
US20230250161A1 (en) 2023-08-10
CL2018003112A1 (es) 2019-02-15
IL262726B1 (en) 2024-03-01
IL262726A (en) 2018-12-31
PE20190261A1 (es) 2019-02-25
JP2019525724A (ja) 2019-09-12
CA3022515A1 (en) 2017-11-09
WO2017191560A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
BR112018072389A2 (pt) anticorpos que reconhecem tau
BR112019022906A2 (pt) Anticorpos que reconhecem tau
BR112018072394A2 (pt) anticorpos que reconhecem a tau
BR112015022260A8 (pt) imunoterapia com tau
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
ECSP18000844A (es) Anticuerpos de unión a tau
MA53434A (fr) Anticorps anti-tigit
MA47268A (fr) Anticorps anti-gpc3
MA52884A (fr) Anticorps anti-il-11
BR112021016947A2 (pt) Anticorpos que reconhecem tau
MA41124A (fr) Compositions en suspension à libération prolongée à rétention gastrique
CU20190006A7 (es) Composiciones para inhibir masp-3
ECSP18000887A (es) Anticuerpos de unión a tau
CO2021007370A2 (es) Anticuerpos que reconocen tau
MA52366A (fr) Anticorps anti-tl1a optimisés
MA52152A (fr) Anticorps
MA51134A (fr) Anticorps anti-alpha-synucléine
CU20210039A7 (es) Anticuerpos que reconocen tau
DE112019001771A5 (de) Reibteil
MA51135A (fr) Anticorps anti-alpha-synucléine
MA50654A (fr) Anticorps anti-pacap
MA49037A (fr) Souche depseudomonas putida
DE112018006116A5 (de) Reibteil
MA49257A (fr) Anticorps anti-trkb

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]